NSE: DIVISLAB | BSE: 532488

Expensive Performer

Download real time

6031.50 29.00 (0.48%)

819.0K NSE+BSE Volume

NSE 10 Sep, 2025 3:31 PM (IST)

160,117.4

Market Cap

Market Runner Up

0.7

Beta 1Year

Very Low volatility

Divi's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DIVISLAB, BSE:532488 Divi's Laboratories Ltd.

Divi's Laboratories Ltd.

06 Feb 2017

6031.50

0.48%

Divis Laboratories Ltd Q3FY17 results comment

Results Update: Divi's Laboratories Ltd.

HDFC Securities

Revenue decreased by 2.95% to Rs. 973.44 Cr in Q3FY17 when compared to the previous quarter. On the other hand, it grew by 13.37% when compared with Q3FY16.

Divi's Laboratories Ltd. is trading below all available SMAs

Divi's Laboratories Ltd.

17 Nov 2016

6031.50

0.48%

Divi's Laboratories

Buy: Divi's Laboratories Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenue grew 4% YoY to | 1005 crore (I-direct estimate: | 1090 crore) mainly due to 35% YoY growth in Carotenoids business to...

Deven Choksey released a Accumulate report for Divi's Laboratories Ltd. with a price target of 6499.0 on 29 Aug, 2025.

Divi's Laboratories Ltd.

14 Nov 2016

6031.50

0.48%

Divi's Lab: Tepid Revenue growth and one time exgratia impacts margins (Nov 14, 2016)

Sell: Divi's Laboratories Ltd.

Karvy

Divis Lab Net revenues are up 3.4% YoY to Rs 10.30 bn lower than our expectation of Rs 11.5 bn for the quarter due to higher base impact, product mix and better performance in Carotenoids. The Operating margins stood at 29% (lower than our estimate of 32.1%) as against 38.7% in Q2FY16 on account of onetime bonus on completion of 25 years and higher other expenses including forex loss and ex-gratia to research. Net Profit was down by 24% YoY to Rs 2232 mn (lower than our estimates of Rs 2,759 mn).

Number of FII/FPI investors increased from 922 to 990 in Jun 2025 qtr.

Divi's Laboratories Ltd.

17 Aug 2016

6031.50

0.48%

Divi's Laboratories

Buy: Divi's Laboratories Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 24.6% YoY to | 1008.1 crore (I-direct estimate: | 932.6 crore) due to ~26% growth in generic business to | 501 crore and ~22% growth in custom synthesis (CS) business to | 443 crore EBITDA margins increased 273 bps YoY to 40% (I-direct estimate: 37%) mainly due to a better product mix. EBITDA increased ~34% YoY to | 403.8 crore (I-direct estimate: | 345.1 crore) Net profit witnessed YoY increase of ~23% to | 301.8 crore (I-direct...

Divi's Laboratories .. has an average target of 6414.33 from 6 brokers.

Divi's Laboratories Ltd.

16 Aug 2016

6031.50

0.48%

Divis Lab Q1FY17 Update 16Aug2016

Neutral: Divi's Laboratories Ltd.

Target

Phillip Capital

Top takeaways from Q1FY17: Delivered strong Q1 operating performance with 17% beat in earnings supported by 310bps positive surprise in margins and 6% beat in revenues. Guides for delayed commercialisation of its new projects –at Kakinada SEZ as well as at Vizag – during late FY18. This could hurt the modelled sales growth of 19% in FY18. Divi’s board has approved a one?time ex?gratia of Rs 790mn for its employees on the occasion of its 25th anniversary and that would hurt FY17 margins by ~150bps. Phillip Capital maintain their Neutral rating with raised TP of Rs 1200 (vs. Rs 1190 earlier).

Divi's Laboratories Ltd. is trading below all available SMAs

Divi's Laboratories Ltd.

13 Aug 2016

6031.50

0.48%

Divi's Laboratories: Strong operational performance; capacity constra

Neutral: Divi's Laboratories Ltd.

Motilal Oswal

In 1Q, Divis's revenues grew 25%YoY (4% beat) to INR10.1b whereas EBITDA grew 34%YoY (~11% beat) to INR4.0b and margins improved 275bp YoY to 39.9%, led by better product mix and lower raw material cost. Though product mix change is expected to normalize going forward, benefits accruing from lower raw material cost can help boost margins for few more quarters. Proportion of generics remained similar: API generics (56% of sales) grew 27%YoY to INR5.6b in 1Q. CRAMS business (44% of sales) growth was ~22%YoY....

Number of FII/FPI investors increased from 922 to 990 in Jun 2025 qtr.

Divi's Laboratories Ltd.

01 Jun 2016

6031.50

0.48%

Divi's Laboratories

Buy: Divi's Laboratories Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 34.1% YoY to | 1095 crore (I-direct estimate: | 963 crore). The generics business grew 47% to | 566 crore (I-direct...

Number of FII/FPI investors increased from 922 to 990 in Jun 2025 qtr.

Is Divi's Laboratories Ltd. worth buying?

750 Votes:

Buy 78.0%

Sell 15.07%

Hold 6.93%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf